Western World
Developing World
Patents
TALKING HEADS: A service that fills the follow-up gap
Nov 30, 2011
As World AIDS Day on Thursday approaches, Kim Hoepfl looks at an NGO that helps keep HIV-positive workers productive.
Biohealthcluster / ABL-DeepChek™
Sep 2, 2011
International Workshop on HIV&HEPATITIS VIRUS
Aug 2, 2011
ABL is pleased to announce an abstract and poster presented at the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies (Los Cabos, Baja California Sur, Mexico, June 7-11, 2011).
The poster “A Fully Integrated and Simplified HIV Clinical Genotyping Solution Using 454 Ultra-Deep-Sequencing and the DeepChek™-HIV system” was presented by Dr Roger Parades behalf on the PRIUS study team.
Click here to receive the poster by email
Comments of PRIUS-I study :
http://www.aidsbeacon.com/news/2011/06/17/better-assessment-of-drug-resistance-may-improve-treatment-of-people-with-hiv-aids/
TherapyEdge® Launches the HIV eRegister for Windows
Aug 2, 2011
AREVIR 2011
Aug 2, 2011
Program of the meetingClick here to see Dr Sayada’s presentation
EASL 2011 in Berlin
Aug 2, 2011
TherapyEdge® ABL SA and BioLiveScale SA are pleased to announce their participation to the EASL 2011 in Berlin
TherapyEdge® Liver Diseases ModuleLast updated FibroMeters presentation (EASL 2011)
454 Ultra-Deep-Sequencing and the DeepChek™-HIV system
Aug 1, 2011
A Fully Integrated and Simplified HIV Clinical Genotyping Solution Using 454 Ultra-Deep-Sequencing and the DeepChek™-HIV system
Click here to receive the poster presentation by email
TherapyEdge® Liver Diseases
Aug 1, 2011
ABL is pleased to announce a cooperation in the field of viral hepatitis infections with Roche Diagnostics Spain and CIBEREHD a research network of experts in viral hepatitis and liver diseases. The TherapyEdge® platform combined with the DeepChek™ Hepatitis software for the management of ultra-deep-sequencing (UDS) information will be used for the data collection, storage and analysis.
4-traders, June 4th, 2011
Click here for more information about this collaboration
Roche 454 Life Sciences, Penzberg, Germany – April 6, 2011
Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C
Trade News
Apr 6, 2011
Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C.
ABL is partnering to the European Network TINN2
Mar 22, 2011
ABL is pleased to announce its participation to the recently launched TINN2 (Treat Infections in Neonates 2) program. TINN2 is a European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Program of the 7th Framework Program.
ABL will participate to this European research network of excellence and provide the centralized IT platform to collect pharmacological and clinical trial data to the researchers for the evaluation of azythromycin for the treatment of infections in preterm and term neonates. The network will work on evaluating various pediatric formulations across Europe in order to apply for a Pediatric-Use Marketing Authorization (PUMA) application and ultimately, to improve neonatal care as a direct benefit to children, their families and health professionals.
See the brochure
European Workshop on HIV & Hepatitis congress
Feb 1, 2011
ABL is pleased to announce a poster presentation at the European Workshop on HIV & Hepatitis congress that will be held in Paphos (Cyprus) from the 23rd to the 25th of March 2011. Asbtract P47, A bioinformatics analysis framework for clinical management of HIV-infected patients using HIV-1 drug resistance and minority variants. Rodriguez et al.
FibroMeters : the most reliable tests of liver fibrosis.
Feb 1, 2011
See the presentation
TherapyEdge® & ViroScore® at the GeSIDA congress
Feb 1, 2011
ABL is pleased to announce the presentation of the Spanish version of TherapyEdge® & ViroScore® at the GeSIDA congress that will be held in Madrid from the 21st to the 24th of October 2009.
- TherapyEdge® & RIS (Red Española de Investigación en SIDA) licensing partnership.
TherapyEdge® se complace de anunciar la disponibilidad de la versión 2009 del algoritmo de interpretación de resistencia a los fármacos para el VIH de la RIS (www.retic-ris.net), integrada dentro del paquete TherapyEdge® – ViroScore® (versión 3.9.2). Ahora, los usuarios de TherapyEdge® – ViroScore, se beneficiarán de la habilidad de los expertos españoles en los términos de la determinación de la resistencia del VIH, además de los otros 6 algoritmos internacionales de interpretación de resistencia a los fármacos para el VIH (Stanford University, ANRS French resistance interpretation rules, Rega institute, Detroit Medical Center, RenaGeno from Brazil and CHL from Luxemburg). - TherapyEdde y Roche Diagnostics SL partnership.
TherapyEdge® y Roche Diagnostics SL han establecido un acuerdo de colaboración en España para la promoción de soluciones conjuntas destinadas al diagnóstico, seguimiento y tratamiento de los pacientes infectados con VIH.”
TherapyEdge® ABL SA and BioLiveScale SA
Feb 1, 2011
TherapyEdge® ABL SA and BioLiveScale SA are pleased to announce a co-sponsoring of the next Symposium on the management of HIV/HBV-HCV co-infections.See the presentation
BioHealth: newsletter 1
Jan 21, 2011
The Cluster of Health Sciences & Technologies – Luxembourg.
See the press release
Link 1 : Luxinnovation
Link 2 : Portail Luxembourgeois de l’Innovation et de la Recherche
South African Patent
Aug 8, 2011
ABL is pleased to report the South African Patent Office has been issued patent N° 2009/07533 and has been granted for 20 years from the filing date, April 10, 2008. This patent is related to the Emory Patent Internal Application WO/2008/124192.
Luciano et al. patent 6,063,028 et patent 6,317,731
Aug 2, 2011
Barry et al. patent 6,081,786 et patent 6,188,988
Aug 2, 2011
This patent is related to the ABL US Patents 6,081,786 and 6,188,988 from Barry et al. See the allowance
ABL has also received 2 new certificates following the re-examination requests for ABL US Patents 6,081,786 and 6,188,988. No claims were invalidated or amended for both patents.
New 6081786 patent certificate, New_6188988_patent_certificate
Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705
Mar 22, 2011
International Publication
http://www.emory.edu/home/index.html
ABL is pleased to report the Canadian Patent Office has been issued patent N° 2326579 and has been granted for 20 years from the filing date, April 1, 1999.
Mar 22, 2011
This patent is related to the ABL US Patents 6,081,786 and 6,188,988 from Barry et al.
Link to the issued patent
ABL Announces the Strengthening of Its Patent Estate: Notice of Allowance in Canada, Issuance of a Patent in India, and Issuance of Reexamination Certificates in the United States after Several Patent Reexaminations
Feb 1, 2011
ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL’s TherapyEdge®-ViroScore® Platform
Feb 1, 2011
LUXEMBOURG–(BUSINESS WIRE)–Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA’s HIV resistance interpretation system.
ABL will offer virco®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge® HIV. virco®TYPE HIV-1 results (raw data and report) will be available together with full patient’s details and will support the healthcare providers’ virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.
ABL Licensed CRP-Santé COMET Subtyping Tool
Feb 1, 2011
Advanced Biological Laboratories (ABL) S.A. and Luxembourg Centre de Recherche Public pour la Santé CRP-Santé announced a non-exclusive licensing and distribution agreement to implement CRP-Santé COMET subtyping tool on ABL TherapyEdge® Platform.
Centro de Genomas®
Feb 1, 2011
ABL is pleased to announce that Centro de Genomas® is as of Oct 15th 2009 the TherapyEdge® local agent in Brazil and will present the TherapyEdge® and ViroScore® products at the “XVI Congresso Brasileiro de Infectologia” which will be held from October the 18th to October the 21st at Maceió, BRAZIL.
See the brochure
The United States Patent & Trademark Office (USPTO)
Feb 1, 2011
See the Ex Parte Reexamination Certificate here
ABL and Evivar Medical enter into Agreements to form a global strategic partnership and IP cross-licensing for disease management and personalized healthcare of Hepatitis B and HIV infections
Jan 21, 2011
Agreement with CIDRZ
Aug 8, 2011
ABL is pleased to announce the agreement with CIDRZ (Centre for Infectious Diseases Research in Zambia) for the use of ViroScore® Suite at their facilities for the management of the HIV sequences. The TherapyEdge® clinical software is part of the agreement for the clinical documentation of HIV drug resistance data. More details to come soon.
ABL, SA :: Solutions for HIV Disease Management
Jan 21, 2011
TherapyEdge® and RightToCare Successfully Launch the New TherapyEdge® Down Referral Software Patient Management SystemSee the press release
TherapyEdge® (ABL group) and TCELS
Jan 21, 2011
TherapyEdge® (ABL group) and TCELS To Cooperate for the National HIV/AIDS Surveillance Program in Thailand Using The TherapyEdge®-ViroScore® SystemSee the press release
TherapyEdge®, ABL and MSH
Jan 21, 2011
TherapyEdge®, ABL and MSH Enter into Agreement to Collaborate on Integration of Software for the Management of HIV, TuberculosisSee the press release
Advanced Biological Laboratories (ABL) and PharmAccess Foundation
Jan 20, 2011
Advanced Biological Laboratories (ABL) and PharmAccess Foundation Enter Licensing Agreement to Support the PASER StudySee the press release